CTRI/2017/06/008791已完成2 期
An open label, multi-center, prospective clinical study to Evaluation of Efficacy and Safety of JPF-16 Capsules in Sexual Dysfunction in Females - NI
Chatarubhuj Pharmaceutical Co0 个研究点目标入组 30 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Diagnosis of Female Sexual Interest/Arousal Disorder according to the DSM-5 criteria (2013)
- •2. Be involved in a stable relationship and have a partner
- •3. Healthy according to normal results of medical history, physical examination, laboratory values, and vital signs; exceptions may be made if the investigator considers an abnormality to be clinically irrelevant
排除标准
- •1.Subjects with major illnesses and sexual dysfunction due to anatomical, surgical or pharmacological causes
- •2.Subjects with history of major psychiatric disorder
- •3.Subjects with history of central nervous system disorders such as stroke, transient ischemic attacks or spinal cord injury or pelvic surgery
- •4.Subjects with hypotension or uncontrolled hypertension, uncontrolled diabetes, hepatic impairment, renal impairment or hematological disorders
研究者
相似试验
已完成
2 期
Clinical study on Ayuvita Forte Capsule in irregular periods with cysts in ovary.CTRI/2019/11/022183Welex Laboratories Pvt Ltd25
招募中
4 期
A study to assess the safety and efficacy of fixed dose combination of Montelukast 10 mg plus Acebrophylline SR 200 mg tablet in patients having bronchial asthmaCTRI/2020/02/023237Sun Pharma Laboratories Limited
已完成
不适用
A clinical trial to test the safety and effectiveness of Neuralzhein in management of memory loss related to age.CTRI/2019/08/020711exxus Laboratories DBA OPUS PHARMA
已完成
3 期
To evaluate safety and performance of CREDENCEâ?¢ BtK Sirolimus Eluting BioResorbable Peripheral Scaffold System in subjects with Critical Limb Ischemiafollowing Percutaneous Transluminal Angioplasty of below the knee arteries.CTRI/2016/11/007473Meril Life Sciences Pvt Ltd30
已完成
3 期
Clinical trial to assess the safety and the efficacy of a new intravenous immune globulin (IGIV3I Grifols10%) in patients with idiopathic (immune) thrombocytopenic purpura.CTRI/2009/091/000860Spectrum Clinical Research Pvt Ltd75